246 related articles for article (PubMed ID: 24692332)
1. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
Nagaraja V; Hays RD; Khanna PP; Spiegel BM; Chang L; Melmed GY; Bolus R; Khanna D
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1725-30. PubMed ID: 24692332
[TBL] [Abstract][Full Text] [Related]
2. Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales.
Spiegel BM; Hays RD; Bolus R; Melmed GY; Chang L; Whitman C; Khanna PP; Paz SH; Hays T; Reise S; Khanna D
Am J Gastroenterol; 2014 Nov; 109(11):1804-14. PubMed ID: 25199473
[TBL] [Abstract][Full Text] [Related]
3. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium.
McMahan ZH; Frech T; Berrocal V; Lim D; Bruni C; Matucci-Cerinic M; Smith V; Melsens K; Proudman S; Zhang J; Mendoza F; Woods M; Khanna D
J Rheumatol; 2019 Jan; 46(1):78-84. PubMed ID: 30442827
[TBL] [Abstract][Full Text] [Related]
5. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.
Bodukam V; Hays RD; Maranian P; Furst DE; Seibold JR; Impens A; Mayes MD; Clements PJ; Khanna D
Rheumatology (Oxford); 2011 Feb; 50(2):330-4. PubMed ID: 20884655
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic.
Khanna D; Maranian P; Rothrock N; Cella D; Gershon R; Khanna PP; Spiegel B; Furst DE; Clements PJ; Bechtel A; Hays RD
Value Health; 2012 Jan; 15(1):128-34. PubMed ID: 22264980
[TBL] [Abstract][Full Text] [Related]
7. Dutch-Flemish translation and validation of the gastrointestinal symptom scales from the patient‑reported outcomes measurement information system (PROMIS)
van der Ende-van Loon M; Korteling D; Willekens H; Schilders M; Curvers W; Bisschops R; Schoon E; Terwee C
J Patient Rep Outcomes; 2023 Nov; 7(1):125. PubMed ID: 38032401
[TBL] [Abstract][Full Text] [Related]
8. Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales.
Khanna D; Hays RD; Shreiner AB; Melmed GY; Chang L; Khanna PP; Bolus R; Whitman C; Paz SH; Hays T; Reise SP; Spiegel B
Dig Dis Sci; 2017 May; 62(5):1186-1192. PubMed ID: 28251500
[TBL] [Abstract][Full Text] [Related]
9. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
[TBL] [Abstract][Full Text] [Related]
10. Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.
Kwakkenbos L; Thombs BD; Khanna D; Carrier ME; Baron M; Furst DE; Gottesman K; van den Hoogen F; Malcarne VL; Mayes MD; Mouthon L; Nielson WR; Poiraudeau S; Riggs R; Sauvé M; Wigley F; Hudson M; Bartlett SJ;
Rheumatology (Oxford); 2017 Aug; 56(8):1302-1311. PubMed ID: 28431140
[TBL] [Abstract][Full Text] [Related]
11. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis.
Bae S; Allanore Y; Furst DE; Bodukam V; Coustet B; Morgaceva O; Maranian P; Khanna D
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):57-63. PubMed ID: 23910611
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
[TBL] [Abstract][Full Text] [Related]
13. UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis.
Abignano G; Mennillo GA; Lettieri G; Karadag DT; Carriero A; Padula AA; Del Galdo F; Khanna D; D'Angelo S
J Rheumatol; 2021 Sep; 48(9):1422-1426. PubMed ID: 33452163
[TBL] [Abstract][Full Text] [Related]
14. Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration.
Matsuda KM; Sugimoto E; Ako Y; Kitamura M; Miyahara M; Kotani H; Norimatsu Y; Hisamoto T; Kuzumi A; Fukasawa T; Sato S; Yoshizaki A
J Dermatol; 2024 Jun; 51(6):741-751. PubMed ID: 38558171
[TBL] [Abstract][Full Text] [Related]
15. Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.
Zekovic A; Damjanov N
Rheumatol Int; 2017 May; 37(5):735-741. PubMed ID: 28271157
[TBL] [Abstract][Full Text] [Related]
16. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument.
Khanna D; Hays RD; Park GS; Braun-Moscovici Y; Mayes MD; McNearney TA; Hsu V; Clements PJ; Furst DE
Arthritis Rheum; 2007 Oct; 57(7):1280-6. PubMed ID: 17907224
[TBL] [Abstract][Full Text] [Related]
17. Measuring response in the gastrointestinal tract in systemic sclerosis.
Khanna D; Nagaraja V; Gladue H; Chey W; Pimentel M; Frech T
Curr Opin Rheumatol; 2013 Nov; 25(6):700-6. PubMed ID: 24047604
[TBL] [Abstract][Full Text] [Related]
18. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
Lee TH; Lee JS; Park S; Lee KA; Kim HS
Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.
McMahan ZH; Tucker AE; Perin J; Volkmann ER; Kulkarni S; Ziessman HA; Pasricha PJ; Wigley FM
Arthritis Care Res (Hoboken); 2022 Mar; 74(3):442-450. PubMed ID: 33064934
[TBL] [Abstract][Full Text] [Related]
20. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
Baron M; Hudson M; Steele R; Lo E;
J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
